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Abstract
Aims In May 2016, a new version of the European Society of Cardiology (ESC) Guidelines for the management of heart failure
(HF) was released. The aim of this study was to describe the management of HF with reduced ejection fraction after the pub-
lication of ESC Guidelines.
Methods and results The Linx registry is a multicentre, observational, cross-sectional study from 14 Catalan hospitals that
enrolled 1056 patients with HF and reduced left ventricular ejection fraction (≤40%) from 1 February to 30 April 2017 in out-
patient cardiology clinics. Results were compared between hospitals according to their level of complexity in our own registry
and compared with previously published registries similar to ours. Sacubitril/valsartan was prescribed to 23.9% of patients in
our population, as a consequence, use of angiotensin-converting enzyme inhibitor and angiotensin receptor blockers in mono-
therapy decreased to 48.1% and 16.9%, respectively, and prescription of beta-blockers (91.8%), mineralocorticoid receptor an-
tagonists (72.7%), and ivabradine (21.4%) remained similar to previous registries. Target doses of beta-blockers (25.4%),
angiotensin-converting enzyme inhibitors (24.9%), angiotensin receptor blockers (7.7%), sacubitril/valsartan (8.1%), and min-
eralocorticoid receptor antagonists (19.7%) were accomplished in a low proportion of patients. Our results also suggest that
prescription and up-titration of class I HF drugs were greater in hospitals with higher level of complexity.
Conclusions The Linx registry shows an appropriate adherence to pharmacological recommendations from ESC HF Guide-
lines despite a low proportion of patients reached target doses. Almost one-quarter of patients were under treatment with
sacubitril/valsartan a few months after ESC HF Guidelines recommendations.
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Introduction
Heart failure (HF) is a global health issue with a prevalence
between 1% and 2% in Western countries,1,2 an estimated
26 million affected worldwide,3 and one of the leading
sources of health care resource use and expenditure.4
Although in Western countries there is currently a trend to-
wards a reduction in the incidence of HF with reduced ejec-
tion fraction [HFrEF; left ventricular ejection fraction (LVEF)
≤40%],5 it still represents almost one-third of incident HF
cases6 and has a mortality rate of 8.8% at 1 year.7
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Pharmacological management of HFrEF aims to regulate
the physiological compensatory response to low cardiac
output, which in the long-term prompts maladaptive cardiac
remodelling finally leading to chronic HF.8 Blocking the adren-
ergic and the renin–angiotensin–aldosterone systems has
been the classical target of HF drugs.9–11 In addition, drugs
that reduce heart rate through inhibition of sinoatrial cardiac
myocites, such as ivabradine,12 or increase plasma levels of
natriuretic peptides through inhibition of neprilysin, such as
sacubitril/valsartan,13 have shown clinical benefits in the last
decade.
In May 2016, a new version of the European Society of Car-
diology (ESC) Guidelines for the management of acute and
chronic HF was released.14 The document included updated
recommendations regarding the diagnosis, pharmacological
and invasive treatment of these patients, such as introduc-
tion of sacubitril/valsartan as a class I therapy, or recommen-
dations for the early initiation of key HF drugs.
To our knowledge, no major registries of HFrEF outpatients
have been published after the publication of ESC 2016 Guide-
lines.14 The purpose of the present study was thus to (i) de-
scribe the characteristics of a large population HFrEF
patients recruited after ESC 2016 Guidelines14 release, (ii)
compare the pharmacological and invasive management of
HFrEF patients by level of hospital complexity, and (iii) com-
pare this management with those from previous registries.
Methods
Study design and population
The Linx registry is a multicentre, observational, cross-
sectional study from 14 Catalan hospitals (Figure 1) aimed
at assessing the impact of the new ESC 2016 Guidelines14 in
the management of HFrEF outpatients in the real-world
setting.
For the Linx registry, patients were prospectively enrolled
from the outpatient cardiology clinics of each participating
hospital from 1 February to 30 April 2017. This included gen-
eral cardiology clinics (mostly in primary hospitals) as well as
specialized HF clinics (typically in tertiary hospitals). Inclusion
criteria were a diagnosis of HF according ESC 2016 Guide-
lines14 and reduced LVEF (defined by LVEF ≤40% in the most
recent echocardiography during follow-up). Exclusion criteria
were age under 18 years old, use of left ventricular assist de-
vices, or heart transplantation before study entry. All of these
patients were included in the present analysis.
Patients included in the Linx registry were managed
according to the local HFrEF management protocols; at the
time of inclusion, there were no regulatory restrictions to
prescription of angiotensin receptor neprilysin inhibitor
(ARNI). For the present analysis, the outpatient clinic visit in
which patients were included in the study will be considered
the ‘index’ visit.
Data collection
Information on demographic characteristics, HF aetiology, key
HF clinical variables (e.g. LVEF and New York Heart Association
functional class), and relevant co-morbidities was collected by
local researchers using the local medical records. Information
on vital signs and electrocardiographic parameters was ob-
tained from the information generated in the most recent
outpatient clinic visit before study entry. Data on blood sam-
ple tests [including levels of N-terminal pro-B type natriuretic
peptide (NT-proBNP)] and echocardiographic parameters
were obtained from the most recent tests before study entry.
Data on pharmacological therapies [including beta-
blockers, angiotensin-converting enzyme inhibitors (ACEI),
angiotensin receptor blockers (ARBs), mineralocorticoid re-
ceptor antagonists (MRAs), ARNIs, and ivabradine, among
others], their doses, and use of key HF devices [cardiac
resynchronization therapy (CRT) and implantable cardioverter
defibrillator (ICD)] were collected by local researchers at the
end of the index visit.
Definition of hospital type
In order to compare the clinical characteristics and pharmaco-
logical management between hospitals according to their level
of complexity, we classified recruiting centres in three catego-
ries: primary, secondary, and tertiary. Hospitals providing nei-
ther interventional cardiology nor cardiac surgery were
classified as primary centres (six), hospitals providing interven-
tional cardiology but not cardiac surgery were classified as sec-
ondary centres (three), and hospitals providing both were
classified as tertiary centres (five). This classification has been
widely used in previously published HF registries.15
Statistical analyses
Descriptive statistics were used to summarize the characteris-
tics of the study participants, including therapies and drug
doses. Categorical variables are presented as number and
percentage, continuous variables with normal distribution
are presented using mean and standard deviation, and non-
normal continuous variables are presented using median
and interquartile range.
In the comparative analyses by level of hospital complex-
ity, these characteristics were compared using chi-squared
tests for categorical variables, and ANOVA and non-
parametric tests for continuous variables, as appropriate.
The proportion of patients in whom target doses of each
key HF pharmacotherapy were achieved (according to ESC
2016 Guidelines14) was also calculated, overall and by
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hospital type. As a graphical, intuitive summary, these pro-
portions were plotted using a radial graph or ‘radar chart’.26
Although this graph has not been common in HF research,
it allows accommodating in one single image multiple data
(in the present analysis, multiple data on target dose use) in
a more efficient way than traditional bar charts. It also allows
calculating the area of the polygon, and the proportion over
the total area, as summary measures. Specifically, we calcu-
lated the proportion over the total area for four polygons,
as a percentage of the maximum theoretical target dose:
overall (i.e. all hospitals), tertiary, secondary, and primary
hospitals. More details on the calculations performed for
the radial graph are presented in the Supporting Information,
Data S1.
We also compared the overall proportions of users of each
drug type and of HF devices in the Linx registry, with the
results of the Spanish cohort of the ESC Heart Failure Long-
term Registry,16 a similar multicentre registry including 1526
Spanish HFrEF patients, published before the release of the
ESC 2016 Guidelines. Proportions were compared again using
the chi-squared statistic.
Finally, we plotted the present results together with the
results from similar, previously published landmark European
HFrEF registries conducted since 2003, as means to provide
historical context to the present findings.7,17–19
All statistical analyses were centralized in one of the
recruiting centres and were performed using Excel version 16
(Microsoft, Redmond, Washington, USA) and Stata software
version 15.0 (StataCorp, College Station, Texas, USA). A two-
tailed P value <0.05 was considered statistically significant.
Results
Study participants
Between 1 February and 30 April 2017, 1056 HFrEF patients
were prospectively enrolled in the registry; 604
patients (57.2%) were recruited from tertiary hospitals, 144
patients (13.6%) from secondary hospitals, and 308 patients
(29.2%) from primary hospitals.
Demographic characteristics and clinical profile of
the study participants
Table 1 summarizes the characteristics of 1056 HFrEF patients
included in the registry. Overall, mean age was 66.5 years,
and 78.9% of patients were men. Ischaemic cardiomyopathy
was the most frequent aetiology of HF (42.3%), followed by
idiopathic dilated cardiomyopathy (32.7%). Median LVEF
was 30%, and only 14.5% of patients were asymptomatic,
while more than half (58.4%) had mild HF symptoms (New
York Heart Association II). Median NT-proBNP was 1861
pg/mL, and 66.5% of patients had a previous admission for
HF. Left bundle branch block was present in 33.6% of pa-
tients. With regard to co-morbidities, 40% of patients had
atrial fibrillation, 34.7% had chronic kidney disease, and
23.7% had chronic obstructive pulmonary disease.
In hospitals with higher level of complexity, patients were
younger, and ischaemic cardiomyopathy was more frequent
than in less complex centres. There were no differences
Figure 1 Hospital geographical location. 1. Hospital Universitari de Bellvitge (L’Hospitalet de Llobregat), 2. Hospital Clinic (Barcelona), 3. Hospital
Universitari Germans Trias i Pujol (Badalona), 4. Hospital de la Santa Creu i Sant Pau (Barcelona), 5. Hospital Universitari Vall d’Hebron (Barcelona),
6. Hospital Universitari Arnau de Vilanova (Lleida), 7. Hospital del Mar (Barcelona), 8. Corporació Sanitària Parc Taulí (Sabadell), 9. Hospital de Figueres
(Figueres), 10. Hospital de Granollers (Granollers), 11. Hospital Moisès Broggi (Sant Joan Despí), 12. Hospital Sant Joan de Deu de Martorell (Martorell),
13. Hospital de Mataró (Mataró), 14. Hospital de Viladecans (Viladecans). 1–5 tertiary hospitals, 6–8 secondary hospitals, 9–14 primary hospitals.
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Table 1 Demographics and clinical profile of patients
Overall (N = 1056) Tertiary (N = 604) Secondary (N = 144) Primary (N = 308) P value
Demographics
Age (years) 66.5 (12.3) 64.3 (12.3) 67.1 (12.1) 70.4 (11.5) <0.001
Male sex 815 (78.9) 481 (80.8) 98 (74.2) 236 (77.1) 0.162
HF aetiology <0.001
Ischaemic 404 (42.3) 232 (46.0) 55 (38.2) 117 (38.1)
Valvular 70 (7.3) 33 (6.6) 13 (9.0) 24 (7.8)
Hypertensive 22 (2.3) 9 (1.8) 7 (4.9) 6 (1.95)
Alcoholic 29 (3.0) 18 (3.6) 4 (2.8) 7 (2.3)
Other toxics 18 (1.9) 8 (1.6) 10 (5.1) 2 (0.6)
Non-compaction 26 (2.7) 20 (4.0) 3 (2.1) 3 (1.0)
Mixed 41 (4.3) 27 (5.4) 2 (1.4) 12 (3.9)
IDC 312 (32.7) 140 (27.8) 44 (30.6) 128 (41.7)
Others 33 (3.5) 17 (3.4) 8 (5.6) 18 (2.6)
LVEF (%) 30 (25, 35) 31 (25, 35) 30 (25, 35) 30 (25, 35) 0.552
NYHA class <0.001
I 153 (14.5) 65 (10.8) 32 (22.2) 56 (18.2)
II 616 (58.4) 341 (56.6) 92 (63.9) 183 (59.6)
III 265 (25.1) 183 (30.4) 19 (13.2) 63 (20.5)
IV 20 (1.9) 14 (2.3) 1 (0.7) 5 (1.6)
Previous admission 701 (66.5) 396 (65.6) 115 (79.9) 190 (61.9) 0.001
Vital signs
SBP (mmHg) 117.6 (18.6) 115.0 (18.2) 120.9 (17.6) 121.1 (19.0) <0.001
DBP (mmHg) 70.9 (11) 71.7 (10.0) 69.8 (11.3) 69.78 (12.5) 0.020
HR (b.p.m.) 68.9 (12.6) 67.7 (11.6) 70.5 (14.8) 70.4 (13.3) 0.002
Cardiovascular risk factors
Current smoker 136 (12.9) 71 (11.8) 24 (16.7) 41 (13.4) 0.275
Previous smoker 559 (53.7) 337 (56.5) 65 (45.8) 157 (51.8) 0.051
Hypertension 700 (66.4) 389 (64.4) 96 (66.7) 215 (70.0) 0.235
Diabetes mellitus 419 (39.7) 231 (38.3) 60 (41.7) 128 (41.7) 0.528
Dyslipemia 648 (61.5) 371 (61.4) 83 (57.6) 194 (63.4) 0.503
Co-morbidities
OSAS 132 (12.5) 80 (13.3) 19 (13.1) 33 (10.8) 0.551
COPD 250 (23.7) 126 (20.9) 40 (27.8) 84 (27.5) 0.041
Stroke 97 (9.2) 66 (10.9) 10 (6.9) 21 (6.9) 0.081
Vasculopathy 117 (11.1) 70 (11.6) 12 (8.3) 35 (11.4) 0.522
CKD 366 (34.7) 211 (34.9) 44 (30.8) 111 (36.3) 0.516
AF <0.001
No 632 (60.0) 379 (62.8) 83 (57.6) 170 (55.7)
Paroxistic 91 (8.6) 43 (7.1) 22 (15.3) 26 (8.5)
Persist/perman. 144 (13.7) 68 (11.3) 31 (21.5) 45 (14.8)
Non-defined 186 (17.6) 114 (18.9) 8 (5.7) 64 (21.0)
Biomarkers
Haemoglobin (g/dL) 13.4 (1.9) 13.4 (1.8) 13.5 (2.3) 13.3 (1.9) 0.725
Creatinine (mg/dL) 1.1 (0.9, 1.4) 1.1 (0.9, 1.5) 1.1 (0.9, 1.4) 1.1 (0.9, 1.4) 0.619
BNP (pg/mL) 296 (200, 891) 306 (204, 956) 219 (136.9, 335) 1782 (484, 3080) 0.012
NT-proBNP (pg/mL) 1861 (694, 4307) 1418 (635, 4108) 2957 (1182, 4794) 2390 (1022.5, 4424.5) 0.006
Ferritin (ng/mL) 154.5 (72, 284) 143.5 (65, 280) 145 (72, 328) 180 (94, 294) 0.268
TSI (%) 20.3 (15, 28) 21 (15, 29) 18.7 (14.5, 26) 20 (15.6, 28) 0.260
ECG
Rhythm <0.001
Sinus 715 (68.4) 444 (74.0) 93 (64.6) 178 (58.9)
AF 227 (21.7) 118 (19.7) 31 (21.5) 78 (25.8)
Paced 99 (9.5) 34 (5.7) 19 (13.2) 46 (15.2)
Atrial flutter 5 (0.5) 4 (0.7) 1 (0.7) 0 (0)
LBBB 353 (33.6) 194 (32.1) 48 (33.3) 111 (36.5) 0.425
Echocardiography
LVEDD (mm) 63.1 (8.8) 63.8 (9) 62.8 (8.0) 61.8 (8.6) 0.005
E/A 1 (0.7, 1.8) 1.1 (0.7, 2.0) 0.9 (0.7, 1.4) 0.8 (0.6, 1.5) <0.001
LA (mm) 47.3 (8.5) 47.1 (8.8) 47.8 (8.6) 47.4 (7.7) 0.671
MR mod/sev 375 (35.9) 223 (37.2) 37 (25.9) 115 (38.0) 0.026
PH 267 (25.9) 173 (29.1) 27 (19.7) 67 (22.3) 0.019
AF, atrial fibrillation; BNP, brain natriuretic peptide; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DBP, di-
astolic blood pressure; ECG, electrocardiogram; HF, heart failure; HR, heart rate; IDC, idiopathic dilated cardiomyopathy; LA, left atrium;
LBBB, left bundle branch block; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MR, mitral regurgi-
tation; NT-proBNP, N-terminal pro-B type natriuretic peptide; NYHA, New York Heart Association; OSAS, obstructive sleep apnoea syn-
drome; PH, pulmonary hypertension; SBP, systolic blood pressure; TSI, transferrin saturation index.
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between hospital types in terms of sex distribution or median
LVEF. The burden of co-morbidities was also similar across
groups, except for atrial fibrillation and for chronic obstruc-
tive pulmonary disease, which were more frequent in hospi-
tals with lower complexity. Median NT-proBNP levels were
higher in secondary hospitals, whereas the lowest levels were
those of tertiary hospitals. Mean systolic blood pressure and
mean heart rate were slightly lower in patients from tertiary
hospitals compared with the other centres.
Pharmacological management and devices
Figure 2 shows the pharmacological and invasive manage-
ment of our study population. Overall, beta-blockers were
used in 91.8% of patients, ACE-I in 48.1%, ARB in 16.9%,
sacubitril/valsartan in 23.9%, MRA in 72.7%, and ivabradine
in 21.4% patients. CRT and ICD were used in 15.6% and
26.3% of patients, respectively.
In the comparative analyses by level of complexity, beta-
blockers were more frequently prescribed in tertiary hospi-
tals, while renin–angiotensin inhibitors globally were more
frequently prescribed in secondary centres. Primary hospitals
had the highest proportion of patients under treatment with
sacubitril/valsartan (37.2%), whereas there was a trend to-
wards higher prescription of MRAs in hospitals with higher
level of complexity (75.7% in secondary hospitals and 78.1%
in tertiary hospitals).
There was a trend towards greater use of devices (ICD and
CRT) in hospitals with higher complexity; and patients from
tertiary and secondary hospitals had undergone percutane-
ous coronary revascularization more frequently.
Table 2 displays the combinations of drug prescription
among patients. Overall, 62.7% of patients were under treat-
ment with triple therapy (beta-blockers + renin–angiotensin
inhibitors + MRA). In line with the results showed in the pre-
vious paragraphs, there was also a trend towards higher pro-
portion of patients under triple therapy in hospitals with
higher level of complexity.
Specific drugs and drug doses
Table 3 describes the use of specific drugs within each family,
and their mean doses, overall and by level of complexity.
Overall, the most frequently prescribed drugs within each
family were enalapril among ACEI (73.4%, mean dose 12
mg/day), bisoprolol among beta-blockers (54.9%, mean dose
5.6 mg/day), losartan among ARBs (40.6%, mean dose 78
mg/day), and eplerenone among MRAs (65.8%, mean dose
29.7 mg/day). Mean dose of sacubitril/valsartan was 144.8
mg/day, and mean dose of ivabradine was 11 mg/day.
The observations with regard to the most frequently used
drug subtypes were also true across all levels of complexity,
except for valsartan and carvedilol, which were the most fre-
quently used ARB and beta-blocker, respectively, in second-
ary hospitals.
Target doses of key heart failure drugs
The proportion of patients in whom target doses of each
key HF pharmacotherapy were achieved (according to ESC
2016 Guidelines14) is displayed in Figure 3, overall and by
level of hospital complexity. Overall, target doses of ACEI
and beta-blockers were achieved in approximately 25% of
patients, MRA in 20%, while for ARB and ARNI, target
doses were achieved only in less than 10% of patients.
Although tertiary hospitals achieved target doses of ARBs,
MRAs, ivabradine, and ARNI more frequently than the other
centres, for beta-blockers and ACEI, target doses were
achieved more frequently in secondary hospitals. On the other
hand, the lowest adherence to guideline-recommended target
doses was observed in primary centres (graph area 1.7%).
Comparison with prior registries
Table 4 compares the observations from our registry to a sim-
ilar Spanish registry16 published before the release of the ESC
2016 Guidelines. In Linx, the use of ACEI, ARBs, and any
renin–angiotensin inhibitors (ACE-I, ARB, or ARNI) was slightly
lower than in the 2015 registry (before commercialization of
sacubitril/valsartan). There was also a statistically significant
decrease in the use of digoxin after the ESC 2016 Guide-
lines.14 No other statistically significant differences were ob-
served between the two studies.
Temporal trends
The temporal trends in pharmacological and device manage-
ment of outpatients with HFrEF in Europe from 2003
(SWEDE-HEART registry17) to the present (Linx) are presented
in Figure 4, which summarizes the observations from key,
comparable, European HFrEF observational studies. The pro-
portion of patients treated with beta-blockers and ACEI/ARBs
remained stable over time (around 90%), until commercializa-
tion of sacubitril/valsartan, which, as evidenced in our regis-
try, has been associated with a marked decrease in the use
of ACEI. MRA use has steadily increased in the last decade,
so has the use of ICD and CRT.
Discussion
The Linx registry shows that after the release of the ESC 2016
Guidelines,14 use of beta-blockers remained very high in
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Figure 2 Drugs and devices. ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin
inhibitor; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator; MRA, mineralocorticoid receptor antagonist; PCI, percu-
taneous coronary intervention.
Table 2 Combinations of drug prescription
Overall (N = 1056) Tertiary (N = 604) Secondary (N = 144) Primary (N = 308) P value
BB (monotherapy) 60 (5.7%) 26 (4.3%) 2 (1.4%) 32 (10.5%) <0.001
MRA (monotherapy) 6 (0.6%) 5 (0.8%) 0 (0%) 1 (0.3%) 0.40
iRA (monotherapy) 24 (2.3%) 5 (0.8%) 3 (2.1%) 16 (5.3%) <0.001
ACE-I 10 (1%) 3 (0.5%) 2 (1.4%) 5 (1.6%) 0.21
ARB 3 (0.3%) 1 (0.2%) 0 (0%) 2 (0.7%) 0.33
ARNI 9 (0.9%) 1 (0.2%) 1 (0.7%) 7 (2.3%) 0.004
BB + iRA (bitherapy) 190 (18.2%) 94 (15.7%) 29 (20.1%) 67 (22.1%) 0.048
BB + ACE-I 109 (10.5%) 58 (9.8%) 18 (12.5%) 33 (10.9%) 0.612
BB + ARB 34 (3.2%) 16 (2.7%) 9 (6.3%) 9 (3%) 0.087
BB + ARNI 34 (3.2%) 9 (1.5%) 2 (1.4%) 23 (7.6%) <0.001
BB + MRA (bitherapy) 50 (4.8%) 28 (4.7%) 9 (6.3%) 13 (4.3%) 0.66
iRA + MRA (bitherapy) 46 (4.4%) 20 (3.3%) 5 (3.5%) 21 (7%) 0.035
ACE-I + MRA 25 (2.4%) 15 (2.5%) 4 (2.8%) 6 (2%) 0.841
ARB + MRA 8 (0.8%) 2 (0.3%) 1 (0.7%) 5 (1.7%) 0.097
ARNI + MRA 11 (1.1%) 2 (0.4%) 0 (0%) 9 (3%) <0.001
BB + iRA + MRA (triple therapy) 653 (62.7%) 415 (69.2%) 95 (66%) 143 (48%) <0.001
BB + ACE-I + MRA 328 (31.8%) 226 (38.3%) 51 (35.4%) 51 (17.1%) <0.001
BB + ARB + MRA 119 (11.4%) 85 (14.1%) 13 (9%) 21 (7%) 0.004
BB + ARNI + MRA 179 (17.2%) 89 (14.8%) 31 (21.5%) 59 (20.1%) 0.047
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BB,
beta-blockers; iRA, renin–angiotensin inhibitors; MRA, mineralocorticoid receptor antagonist.
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HFrEF patients, while there was a marked decrease in the use
of ACE-I/ARBs in monotherapy, which was likely the
consequence of a marked increase in the use of
sacubitril/valsartan. When considering hospital complexity,
we observed that beta-blockers, MRAs, and devices were
more frequently used in tertiary hospitals (where the popula-
tion was younger and median NT-proBNP levels were lower),
while sacubitril/valsartan was more frequently used in pri-
mary hospitals. In all centres, achievement of the target drug
doses recommended by the ESC 2016 Guidelines14 was low.
Our first main finding is the very high uptake of
sacubitril/valsartan, only a few months after ESC 2016
Guidelines14 recommendation to replace ACE-I for ARNI in
ambulatory patients with HFrEF who remain symptomatic
despite optimal medical treatment. The proportion reached
24% in our population and was even higher in primary hos-
pitals. Given the recent publication of safety data showing
that early initiation of ARNI might be feasible and tolera-
ble,20 this proportion is likely to keep growing in the com-
ing years. Further studies will provide valuable insights on
this question.
Our results also suggest a trend towards a better adherence
to ESC HF Guideline recommendations in hospitals with higher
level of complexity. Whether these disparities are the conse-
quence of differences in the clinical profiles of the patient pop-
ulations from each type of hospital, or of other factors, cannot
be concluded from the available data. Nevertheless, some dif-
ferences in demographic and clinical characteristics were
Table 3 Drug prescription and doses (mg/day)
Overall Tertiary Secondary Primary P value
ACE-I
Enalapril (n, %) 373 (73.4%) 262 (79.6%) 51 (65.4%) 60 (59.4%) <0.001
Mean dose (SD) 12 (9) 12.2 (8.4) 14.7 (11.4) 8.7 (7.8) —
Ramipril (n, %) 118 (23.2%) 58 (17.6%) 23 (29.5%) 37 (36.6%) —
Mean dose (SD) 4.5 (2.8) 4.6 (2.8) 5.3 (3.1) 4.0 (2.6) —
Lisinopril (n, %) 9 (1.8%) 6 (1.8%) 1 (1.3%) 2 (2%) —
Mean dose (SD) 13.1 (15.4) 11.3 (14.3) 5 (0) 22.5 (24.7) —
Captopril (n, %) 1 (0.2%) 0 (0%) 0 (0%) 1 (1%) —
Mean dose (SD) 25 (0) — — 25 (0) —
Perindopril (n, %) 5 (1%) 1 (0.3%) 3 (3.9%) 1 (1.0%) —
Mean dose (SD) 3.6 (2.6) 8 (0) 2 (0) 4 (0) —
Others (n, %) 2 (0.4%) 2 (0.6%) 0 (0%) 0 (0%) —
ARB
Valsartan (%) 63 (37.1%) 39 (35.8%) 16 (66.7%) 8 (21.6%) 0.002
Mean dose (SD) 120.7 (85.1) 115.6 (76.3) 110.9 (83.6) 320 (0) —
Losartan (%) 69 (40.6%) 44 (40.4%) 5 (20.8%) 20 (54%) —
Mean dose (SD) 78 (46.6) 80.4 (44.0) — 68.8 (57.9) —
Candesartan (%) 26 (15.3%) 20 (18.4%) 2 (8.3%) 4 (10.8%) —
Mean dose (SD) 21.8 (16.9) 22.2 (17.8) — 18 (2.8) —
Olmesartan (%) 6 (3.5%) 1 (0.9%) 1 (4.2%) 4 (10.8%) —
Mean dose (SD) 40 (0) — — 40 (0) —
Irbesartan (%) 5 (2.9%) 5 (4.6%) 0 (0%) 0 (0%) —
Mean dose (SD) 150 (0) 150 (0) — — —
Telmisartan (%) 1 (0.6%) 0 (0%) 0 (0%) 1 (2.7%) —
Mean dose (SD) 80 (0) — — 80 (0) —
Beta-blockers
Bisoprolol (%) 519 (54.9%) 268 (48.6%) 66 (48.3%) 185 (71.4%) <0.001
Mean dose (SD) 5.6 (3.3) 6.4 (3.4) 6.5 (3.8) 4.1 (2.4) —
Carvedilol (%) 390 (41.2%) 258 (46.8%) 69 (50.7%) 63 (24.3%) —
Mean dose (SD) 26.6 (18.4) 26.2 (17.4) 33.2 (21.3) 20.8 (16.6) —
Metoprolol (%) 1 (0.1%) 1 (0.2%) 0 (0%) 0 (0%) —
Mean dose (SD) 100 (0) 100 (0) — — —
Nevibolol (%) 35 (3.7%) 24 (4.4%) 0 (0%) 11 (4.3%) —
Mean dose (SD) 4.5 (2.5) 4.7 (2.9) — 4 (1.5) —
Others (%) 1 (0.1%) 0 (0%) 1 (0.7%) 0 (0%)
MRA
Spironolactone (%) 262 (34.2%) 161 (34.2%) 31 (28.4%) 70 (37.6%) 0.275
Mean dose (SD) 28.2 (18.1) 27.6 (18.7) 27.8 (16.7) 29.6 (17.3) —
Eplerenone (%) 504 (65.8%) 310 (65.8%) 78 (71.6%) 116 (62.4%) —
Mean dose (SD) 29.7 (12.5) 31.1 (13.6) 29.9 (11.7) 26.1 (8.7) —
Ivabradine
Mean dose (SD) 11 (3.3) 10.9 (3.6) 11.2 (2.9) 11.1 (2.9) —
Sacubitril/valsartan
Mean dose (SD) 144.8 (94) 160.5 (101) 144.1 (94.4) 130.4 (85.4) —
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; n, num-
ber; SD, standard deviation.
32 F. de Frutos et al.
ESC Heart Failure 2020; 7: 26–36
DOI: 10.1002/ehf2.12567
observed across centres—e.g. patients from tertiary hospitals
were younger, which might explain a higher tolerance to beta-
blockers, and therefore the more frequent use of this drug
group; and patients from secondary and primary hospitals
were older and had more co-morbidities, such as chronic ob-
structive pulmonary disease. Despite the fact that there are
no previous studies comparing management of HFrEF outpa-
tients by hospital type, some studies21–23 also suggest better
outcomes in patients admitted for HF in higher volume
hospitals, although in a recently published registry (GWTG-
HF)24 this trend was not confirmed.
We also observed a low proportion of patients meeting the
recommended target doses of most class I HFrEF therapies. A
potential explanation to this finding, as discussed in the ESC
2016 Guidelines,14 is the fact that some of the clinical trials
in which those target doses were defined were conducted be-
fore the availability of modern therapies such as eplerenone or
sacubitril/valsartan, among others. Also, the patient popula-
tions included in those studies tended to be young and to have
few co-morbidities; conversely, in our real-life patient popula-
tion, the prevalence of key co-morbidities such as chronic kid-
ney disease or chronic obstructive pulmonary disease was
high. In addition, it is important to note that information on
drug use, drug doses, and device usewas recorded at study en-
try (i.e. not necessarily at end of titration). This means that
many patients might have been treated with additional thera-
pies, might have had some drug doses titrated, or might have
been treated with specific HF devices later in time (i.e. during
follow-up in the cardiology clinic), as part of standard pharma-
cological titration and progressive therapeutic optimization.
Therefore, the present observations regarding target doses
and device use should be interpreted cautiously.
Importantly, our findings regarding the very low proportion
of patients meeting target doses are consistent with those
from prior registries.7,17–19,25 Indeed, achieving target doses
of pharmacological therapies proven to reduce mortality
Figure 3 Target dose. ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhib-
itor; MRA, mineralocorticoid receptor antagonist.
Table 4 Drugs prescription comparison with previous registries
from Spain
ESC Heart Failure
Long-term Registry17
(LVEF ≤ 40%)
(N = 1526)
Linx registry
(N = 1056) P value
ACE-I (%) 64.6 48.1 <0.001
ARB (%) 29.1 16.9 <0.001
ARNI (%) — 23.9 —
ACE-I + ARB + ARNI (%) 92.6 86.9 <0.001
Beta-blockers (%) 93.3 91.8 0.15
MRA (%) 74.5 72.7 0.31
Diuretics (%) 83.3 83.5 0.89
Digoxin (%) 22 14.1 <0.001
Ivabradine (%) 19.7 21.4 0.29
Nitrates (%) 16.8 19.7 0.06
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor;
ESC, European Society of Cardiology; LVEF, left ventricular ejection
fraction; MRA, mineralocorticoid receptor antagonist.
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remains as a major challenge for the management of patients
with chronic HFrEF as recently described in CHAMP-HF regis-
try.25 Compared with clinical practice in the USA, we found
no differences in achieving target doses of ACE-I/ARB (20.6%
vs. 17.5%) or beta-blockers (25.4% vs. 27.6%), but we found
fewer patients in target doses regarding ARNI (8.1% vs. 14%)
and MRA (19.7% vs. 76.6%). The greater proportion of target
doses of MRA might be partly explained by a much lower pro-
portion of patients prescribed with MRA (72.7% vs. 33.1%)
that might select a group of patients with better renal
function.
Study strengths
To our knowledge, this is the first registry to evaluate the
real-world management of HFrEF in the outpatients setting
in Europe since the publication of the ESC 2016 HF Guide-
lines. Moreover, because Linx is a multicentre, large registry,
this maximized statistical power and the generalizability of
the conclusions. In addition, because not only tertiary but
also secondary and primary centres were included, we were
able to compare hospitals by level of complexity, and this in-
creased generalizability of our overall findings even further.
Although secondary and primary centres are usually under-
represented in clinical trials and observational studies, they
actually manage a large number of patients in routine clinical
practice. Finally, the detailed information on drug dosage
captured in Linx allowed evaluating adherence to guideline
recommendations.
Study limitations
One of the major limitations of the registry comes from the
cross-sectional design, which limits causal inference based on
the observed differences. Another limitation is the absence
of information in the registry describing the reason for not pre-
scribing or up-titrating medication or devices. It is highly likely
that formal contraindications as well as limited tolerance to
specific drugs would explain most of these scenarios. Finally,
although participating hospitals are spread around Catalonia,
most patients were recruited from the metropolitan area of
Barcelona, so patients from rural areas might have been
underrepresented.
Conclusions
The Linx registry shows an appropriate adherence to pharma-
cological recommendations from ESC 2016 HF Guidelines de-
spite that target doses of class I HF drugs were low in our
population. These findings are consistent with the observa-
tions from prior observational, real-life studies. On the other
Figure 4 The temporal trends in pharmacological and device management of outpatients with heart failure with reduced ejection fraction in Europe.
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BB, beta-blockers;
CRT, cardiac resynchronization therapy; ESC-HF-LT, European Society of Cardiology Heart Failure Long-Term Registry; ICD, implantable cardioverter de-
fibrillator; MRA, mineralocorticoid receptor antagonist.
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hand, almost one-quarter of chronic HFrEF patients were un-
der treatment with sacubitril/valsartan a few months after
ESC 2016 HF Guidelines recommendation, prompting the re-
duction of ACE-I/ARB use in this patient population. Use of
sacubitril/valsartan was even greater in primary hospitals. Fi-
nally, use of beta-blockers, MRA, and ivabradine remained
similar to the prescription rates observed in previous Spanish
HFrEF registries and was particularly high in tertiary centres.
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